Importantly, we were able to validate these findings using low-passage cancer cell lines (UM18 and UM59) derived from human primary PDA samples, where silencing of ATDC significantly inhibited CD44, Snail1, and Zeb1 expression (Supplemental Fig. 12D). Here, TRIM29 is linked to Patent ductus arteriosus.